Sample size requirements for evaluation of bridging evidence

Biometrical Journal

Volumn 44, Issue 8, 2002, Pages 969-981

  Liu, Jen Pei ^a,b   Hsueh, Hueymiin ^c   Chen, James J ^d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

^d NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Equivalence limit; Extrapolation; Hierarchical Model; Similarity

Indexed keywords

DRUG PRODUCTS; HIERARCHICAL SYSTEMS;

CLINICAL DATA; CLINICAL DRUGS; DATA PACKAGES; DRUG DEVELOPMENT; EQUIVALENCE LIMIT; HIERARCHICAL MODEL; PHARMACEUTICAL PRODUCTS; SAMPLE SIZES; SIMILARITY; STATISTICAL EVALUATION;

EXTRAPOLATION;

EID: 0036931168     PISSN: 03233847     EISSN: None     Source Type: Journal    
DOI: 10.1002/bimj.200290008     Document Type: Article

References (30)

1. Blackwelder, W.C., 1982: "Prove the null hypothesis" in clinical trials. Controlled Clinical Trials, 3, 345-353.
2. Durrleman, S., and Simon, R., 1990: Planning and Monitoring of equivalence studies. Biometrics, 46, 329-336.
3. Dunnett, C.W., and Gent, M., 1977: Significance testing to establish equivalence between treatments with special reference to data in the form of 2 × 2 table. Biometrics, 33, 593-602.
4. nd Edition, Revised and Expanded, Marcel Dekker, Inc., New York, New York.
5. Chow, S.C., Shao, J., and Hu, O.Y.P., 2001: Bridging Studies for Clinical Development, Submitted for publication.
6. Ebbutt, A.F., and Frith, L., 1998: Practical issue in equivalence trials. Statistics in Medicine, 17, 1691-1701.
7. Ellenburg, S.S. and Temple, R., 2000: Placebo-controlled trials and active-controlled trials in the evaluation of new treatment, part 2: practical issue and specific cases. Annals of Internal Medicine 133, 464-470.
8. Fisher, L.D., Gent, M., and Buller, H.R., 2001: Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. American Heart Journal 141, 26-32.
9. Fleiss, J.L., 1986: Analysis of data from multiclinic trials, Controlled Clinical Trials 7, 267-275.
10. Fleming, T.R., 2000: Design and interpretation of equivalence trials. American Heart Journal 139, 172-176.
11. ICH, 1997: International Conference on Harmonisation Tripartite Guidance E 5 on Ethnic Factors in the Acceptability of Foreign Data.
12. ICH, 1998: International Conference on Harmonisation Tripartite Guidance E 9 on Statistical Principles for Clinical Trials.
13. Hung, H.M.J., 2001: Noninferiority: A dangerous toy. ICSA Bulletin, Jan., 27-29.
14. Jennison, C., and Turnbull, B.W., 1993: Sequential equivalence testing and repeated confidence intervals, with applications to normal and binary responses. Biometrics 49, 31-43.
15. Knodell, R.G., Ishak, K.G., Black, W.C., et al., 1981: Formulation and application of a numerical scoring system for assessing histological activity in asymptotic chronic active hepatitis, Hepatology 1, 431-435.
16. Liu, J.P., 1995: Letter to the Editor on "Sample size for therapeutic equivalence based on confidence interval" by S.C. Lin. Drug information Journal 29, 1063-1064.
17. Liu, J.P. and Chow, S.C., 1992: Sample size determination for the two one-sided tests procedure in bioequivalence, Journal of Pharmacokinetics and Biopharmaceutics 20, 101-104.
18. Liu, J.P. and Weng, C.S., 1995: Bias of two one-sided tests procedures in assessment of bioequivalence. Statistics in Medicine 14, 853-862.
19. Makuch, R.W. and Simon, R., 1978: Sample size requirements for evaluating a conservative therapy. Cancer Treatment Report 6, 1037-1040.
20. Makuch, R.W. and Johnson, M., 1989: Issues in planning and interpreting active control equivalence studies. Journal of Clinical Epidemiology 42, 503-511.
21. Prentice, R.L., Smythe, R.T., Krewski, D., and Mason, M., 1992: On the use of historical control to estimate dose response trends in quantal bioassay, Biometrics 48, 459-478.
22. Rohmel, J., 1998: Therapeutic equivalence investigations: statistical considerations. Statistics in Medicine, 17, 1703-1714.
23. Siegel, J.P., 2000: Equivalence and noninferiority. American Heart Journal 139, 166-170.
24. Simon, R., 1999: Bayesian design and analysis of active control clinical trials, Biometrics 55, 484-487.
25. Snapinn, S.M., 2001: Alternative for discounting historical data in the analysis of noninferiority trial. ICSA Bulletin Jan., 29-33.
26. Tarone, R.E., 1982: The use of historical control information in testing for a trend in proportions, Biometrics 38, 215-220.
27. Temple, R. and Ellenburg, S.S., 2000: Placebo-controlled trials and active-controlled trials in the evaluation of new treatment, part 1: ethnical and scientific issues. Annals of Internal Medicine 133, 464-470.
28. Tsong, Y., Wang, S.J., Cui, L., and Hung, J.H.M., 2001: Placebo control, historical control, and active control trials, ICSA Bulletin Jan., 36-39.
29. Witties, J., 2001: Active-control trials: a linguistic problem. ICSA Bulletin Jan., 39-40.
30. Yates, F., 1934: The analysis of multiple classifications with unequal numbers in the different classes, Journal of the American Statistical Association 29, 51-66.